The Latest Breaking News from MRK

Analysts Just Issued Upgrades on These 4 Buy-Rated Stocks

The blistering inflation and rising recession odds have led to low consumer sentiment. And the market volatility is expected to remain in the near term. So, we think fundamentally solid stocks Lamar Advertising (LAMR), EPR Properties (EPR), Merck & Co. (MRK), and Tenaris (TS), which analysts recently upgraded, could be…

StockNews.com · Jul 8, 2022

Looking At Merck & Co's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 15 strange trades.

Benzinga · Jul 5, 2022

4 Pharmaceutical Stocks with Tremendous Growth Potential

The global pharmaceutical industry has witnessed robust growth over the past few years. The rapidly aging population and continued breakthroughs in drug development are expected to keep driving the industry’s growth. Thus, we think pharmaceutical stocks Assertio Holdings (ASRT), Bayer (BAYRY), Eagle Pharmaceuticals (EGRX), and Merck (MRK), which possess solid…

StockNews.com · Jun 29, 2022

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Benzinga · Jun 21, 2022

Merck To Start Pivotal Trial For Next-Gen Pneumococcal Vaccine Next Month

Merck & Co Inc (NYSE:MRK) presented results from the Phase 1/2 study, evaluating V116 in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2).  Data were shared at the International Symposium on Pneumococci and Pneumococcal Diseases. V116 targets serotypes that account for 85% of…

Benzinga · Jun 21, 2022

3 Drug Manufacturers to Buy on the Pullback

The global pharmaceutical industry is expected to thrive with the lingering impact of COVID-19 and the evolving healthcare landscape. Given the industry’s solid prospects, the pullbacks in drug manufacturing stocks Merck & Co (MRK), Bristol-Myers Squibb (BMY), and Bayer Aktiengesellschaft (BAYRY) amid the broader market correction preset solid buying opportunity.…

StockNews.com · Jun 20, 2022

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

Benzinga · Jun 17, 2022

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

StockNews.com · Jun 16, 2022

Merck & Co Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 10 strange trades.

Benzinga · Jun 15, 2022

Dogs of the Dow: 4 Stocks to Buy Now

Market sentiment was mostly unchanged on Monday, as investors await the May inflation report. Given the market uncertainties, we think investing in high-yielding dividend stocks that are part of the Dow Jones index—commonly known as the Dogs of the Dow—might the ideal strategy now. And our top choices among these…

StockNews.com · Jun 7, 2022